Sandoz Archives | Page 3 of 4

Home / Posts tagged Sandoz (Page 3)

Sandoz Acquires CIMERLI® Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market

CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* [...]

Sandoz US Subsidiaries Resolve Generic Drug Antitrust Class Action Litigation with Direct Purchaser Class Plaintiffs

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if approved by Court Basel, February 29, 2024 – Sandoz [...]

Sandoz Announces Changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication [...]

Sandoz Launches First and Only Biosimilar for Multiple Sclerosis, Tyruko® (natalizumab), in Germany

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS) Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024 (Korea Bizwire) – [...]

Sandoz Announces Agreement to Acquire CIMERLI® Business from Coherus, Strengthening Position in US Market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US [...]

Sandoz Launches Hyrimoz® (adalimumab) High-concentration Formulation in Europe, Aiming to Improve Patient Care

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across Europe Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in Europe Basel, November 21, 2023 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; [...]

Sandoz Inaugurates New Antibiotic Production Plant in Austria and New Biosimilar Development Center in Germany

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help secure European-based supply Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business Basel, November 10, 2023 (Korea Bizwire) – Sandoz, the global leader in generic [...]

Sandoz Successfully Issues EUR 2.0 Billion Inaugural Eurobonds

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million Maturities of 3.5, 6.5 and 10 years, carrying fixed coupons at 3.97%, 4.22% and 4.50%, respectively Proceeds to repay bridge loan facility and for [...]

Sandoz Successfully Issues CHF 750 Million in Inaugural Bonds

Highly successful inaugural CHF senior bonds priced earlier today Two tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectively Proceeds to partially repay bridge loan facility and for general corporate purposes Basel, October 26, 2023 (Korea Bizwire) – Sandoz, the global leader [...]

Sandoz Reports Year-to-date Sales for the First Nine Months of 2023

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz® launch, approval of Tyruko® in US and Europe, partnership on ustekinumab and closing of Mycamine® acquisition Full-year 2023 guidance confirmed [...]